Form 8-K - Current report:
SEC Accession No. 0001213900-25-055832
Filing Date
2025-06-20
Accepted
2025-06-20 08:00:13
Documents
13
Period of Report
2025-06-20
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0246303-8k_lomond.htm   iXBRL 8-K 29029
2 PRESS RELEASE, DATED JUNE 20, 2025 ea024630301ex99-1_lomond.htm EX-99.1 9849
  Complete submission text file 0001213900-25-055832.txt   204564

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cik0001900520-20250620.xsd EX-101.SCH 3035
4 XBRL LABEL FILE cik0001900520-20250620_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE cik0001900520-20250620_pre.xml EX-101.PRE 22363
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0246303-8k_lomond_htm.xml XML 3361
Mailing Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901
Business Address C/O LOMOND THERAPEUTICS HOLDINGS, INC. 8 THE GREEN STE 8490 DOVER DE 19901 561 464 2841
Lomond Therapeutics Holdings, Inc. (Filer) CIK: 0001900520 (see all company filings)

EIN.: 872959575 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-56377 | Film No.: 251059112
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)